Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Zacks News
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
Amphastar Pharmaceuticals (AMPH) Meets Q2 Earnings Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 42.11% and 6.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
by Indrajit Bandyopadhyay
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
New Strong Sell Stocks for March 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 14.29% and 7.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Amphastar (AMPH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
Amphastar Pharmaceuticals (AMPH) Q3 Earnings Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 15.39% and -8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals (AMPH) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.
Amphastar's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amphastar.
3 Reasons Why Amphastar (AMPH) Is a Great Growth Stock
by Zacks Equity Research
Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns
Why the Earnings Surprise Streak Could Continue for Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress
by Zacks Equity Research
Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress
What Bargain Hunting? Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
by Zacks Equity Research
Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.